Search

Research Trials

Research Trials

Currently Enrolling

If you or someone you know is interested in participating in a research trial with the IU Psychotic Disorders Program please call our 24-hour Study Line at (317) 274-0474.


presto.pngPreliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) "Presto"

PI: Alan Breier, MD

Click here to view official details about this study!

 

 

 

 

 

 

 


 

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia "Stanley"

PI: Alan Breier, MD

 

Click here to view official details about this study!

 


Genetics_flyers.jpgIndiana University Psychotic Disorders Program Genetic Repository

PI:Alan Breier, MD.


Vista_flyer.pngA Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

"VISTA"

PI: Alan Breier, MD

Click here to view official details about this study!


 

Cortical Activation and Cognitive Performance During Repetitive Transcranial magnetic Stimulation in First-Episode Psychosis:

A Pilot Study

"rTMS"

PI: Michael Francis, MD

Click here to view official details about this study!


Flyer_IMT_01.29.14_approved.jpgAn Integrated Metacognitive Approach to Improve Insight and Outcomes in Early Psychosis

"IMT"

PI: Jenifer Vohs, PhD

Click here to view official details about this study!


The Efficacy and Safety of a Selective Estrogen Receptor Beta agonist (LY500307) for Negative Symptoms and Cognitive Impairment

Associated with Schizophrenia

"BETA"

PI: Alan Breier, MD

 

Click here to view official details about this study!


Safety and Efficacy of Fingolimod in Schizophrenia Patients who have Suboptimal Responses to Antipsychotic Drug Treatment

"STEP"

PI: Alan Breier, MD.

Click here to view official details about this study!

 

 


 

A Longitudinal Assessment of Patient Outcomes at The Prevention and Recovery Center for Early Psychosis (PARC)

PI: Emily Liffick, MD



Previous Research Trials

Not Enrolling



"Formal Thought Disorder in First Episode Psychosis: The Role of Affective and Cognitive Load"

"Speech"

PI: Kyle Minor, PhD


 

A Phase III, multi-center, randomized, 12-week, double-blind, parall el-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled treatment period.

"NightLyte"

PI: Alan Breier, MD.

Click here to view official details about this study



A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period.

"SunLyte"

PI: Alan Breier, MD.

Click here to view offial details about this study



IOWA_flyer.jpgEffects of Paliperidone Palmitate vs Oral Antipsychotics on Clinical Outcomes and sMR Measures in First Episode Patients: A Randomized Clinical Trial

"Iowa"

PI:Alan Breier, MD.


"Assessing Metacognition in Recent Onset Schizophrenia: A pilot project"

"MetaCog"

PI: Jenifer Vohs, PhD



An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia

PI: Alan Breier, MD.


A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

PI: Alan Breier, M.D.


A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia

 

PI: Alexander Radnovich, M.D., Ph.D.


A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia

 

PI: Alan Breier, M.D.


A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment with LY2140023 Combined with Standard of Care Compared to Placebo Combined with Standard of Care in the Treatment of Patients with Prominent Negative Symptoms of Schizophrenia (H8Y-MC-HBCO)

PI: Emily Liffick, MD.


A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia

PI: Emily Liffick, M.D.


A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia

PI: Alan Breier, M.D.


A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate With Oral Risperidone in Adults With Recently-Diagnosed Schizophrenia Who Are at

High Risk of Relapse

PI: Alan Breier, M.D.

twitter-red-circle.png  facebook-red-circle.png  instagram-red-circle.png  linkdin-red-circle.png

Department of Psychiatry | 1111 W. 10th Street, PB A212 | Indianapolis, IN | 46202 | (317) 274-1224